MEDIPOST Obtains Patent for its High-Efficient Technology for Culturing Stem Cells2017/06/14STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in UK for its Alzheimer’s Disease Treatment Technique that Uses Stem Cells2017/05/17STEM CELL THERAPEUTIC
Chinese Securities Company Praises MEDIPOST as a “Company with Most Profitable Stem Cell Drug”2017/04/26STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in US for its Next-Generation Stem Cell Culturing Technology2017/01/10STEM CELL THERAPEUTIC
MEDIPOST Signs MOU with Canadian Public-Private Consortium Funded by the Government of Canada2016/12/01STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in China for Its Brain Disease Treatment Technology that Uses Stem Cells2016/11/30STEM CELL THERAPEUTIC
MEDIPOST Completes Phase 1 and 2 Clinical Trials with its Lung Disease Treatment Drug ‘PNEUMOSTEM’ in US2016/06/30STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in US for its Alzheimer’s Disease Treatment Drug2016/06/08STEM CELL THERAPEUTIC
MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease2016/05/03STEM CELL THERAPEUTIC
MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle Indications for CARTISTEM®2023/12/27
MEDIPOST Selected for a Government-Supported R&D Project Worth KRW 13 billion, to be Used for Global Market Expansion Including the U.S.2023/10/04
MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery Clinical Study Results Published in SCI-Level Journal2023/05/02
MEDIPOST Treats First Subject with CARTISTEM® in Japan Phase 3 Clinical Trial, Accelerating Clinical Development efforts in Japan2023/01/16
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01